Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 8/20 | 0.69 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.58 |
| ▸ | CYP11B1 | P15538 | 6/20 | 0.53 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7416330 | 0.90 | NOTUM (0.62) | NOTUMHSD17B3CYP11B2ALDH1A1KDM4E | |
| SCHEMBL30340506 | 0.87 | NOTUM (0.67) | NOTUMHSD17B3ALDH1A1HPGDKDM4E | |
| SCHEMBL399536 | 0.87 | NOTUM (0.67) | NOTUMHSD17B3ALDH1A1HPGDKDM4E | |
| SCHEMBL853846 | 0.85 | PDK1 (0.50) | NOTUMHSD17B3ALDH1A1HPGDKDM4E | |
| Hydrochloric Acid SCHEMBL6572261 | 0.84 | CYP11B1 (0.56) | NOTUMHSD17B3CYP11B1CYP11B2ALDH1A1 | |
| SCHEMBL2061420 | 0.83 | HSD17B3 (0.49) | NOTUMHSD17B3CYP11B1CYP11B2ALDH1A1 | |
| SCHEMBL25321379 | 0.83 | KDM4E (0.59) | NOTUMHSD17B3ALDH1A1HPGDKDM4E | |
| SCHEMBL583556 | 0.83 | ADRB2 (0.55) | NOTUMHSD17B3NPC1TP53MAPT | |
| SCHEMBL30475924 | 0.83 | KDM4E (0.59) | NOTUMHSD17B3ALDH1A1HPGDKDM4E | |
| SCHEMBL7749897 | 0.83 | ADRB2 (0.54) | NOTUMHSD17B3ALDH1A1HPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 200 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2297166-B1 | SUBSTITUTED N-IMIDAZO[2,1-B]THIAZOLE-5-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS | ESTEVE LABOR DR (ES) | 2012-08-01 | — | — | EP | claimed |
| US-20110230478-A1 | 4-Alkyl-substituted diaminopyrimidines | Bayer ScienceCrop AG (DE) | 2011-09-22 | — | — | US | claimed |
| EP-2330904-A2 | 4-ALKYL-SUBSTITUTED DIAMINOPYRIMIDINES | Bayer CropScience AG (DE) | 2011-06-15 | — | — | EP | claimed |
| US-20110105472-A1 | Diaminopyrimidines as crop protection agents | BAYER CROPSCIENCE AG (DE) | 2011-05-05 | — | — | US | claimed |
| WO-2010025863-A2 | 4-ALKYL-SUBSTITUTED DIAMINOPYRIMIDINES | BAYER CROPSCIENCE AG (DE) | 2010-03-11 | — | — | WO | claimed |
| WO-2010025871-A1 | 4-HALOGEN ALKYL-SUBSTITUTED DIAMINOPYRIMIDINES FOR USE AS FUNGICIDES | BAYER CROPSCIENCE AG (DE) | 2010-03-11 | — | — | WO | claimed |
| EP-2161259-A1 | 4-Haloalkyl substituted Diaminopyrimidine | Bayer CropScience AG (DE) | 2010-03-10 | — | — | EP | claimed |
| WO-2009135927-A1 | SUBSTITUTED N-PHENYL-2,3-DIHYDROIMIDAZO[2,1-B]THIAZOLE-5-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-11-12 | — | — | WO | claimed |
| EP-2116546-A1 | Substituted N-phenyl-2,3-dihydroimidazo[2,1-b]thiazole-5-sulfonamide derivatives as 5-HT6 ligands | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-11-11 | — | — | EP | claimed |
| EP-2116547-A1 | Substituted N-imidazo(2, 1-b) thiazole-5-sulfonamide derivatives as 5-TH6 ligands | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-11-11 | — | — | EP | claimed |
| US-20080221116-A1 | ISOXAZOLINE ALPHA 1a/1d ADRENORECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-09-11 | — | — | US | claimed |
| WO-2008033513-A1 | ISOXAZOLINE ALPHA 1a/1d ADRENORECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-20 | — | — | WO | claimed |
| US-20060116368-A1 | 4-Piperidinecarboxamide modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-01 | — | — | US | claimed |
| WO-2006058338-A2 | 4 - PIPERIDINECARBOXAMIDE DERIVATIVES AS MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-01 | — | — | WO | claimed |
| US-12528810-B2 | Small molecule inhibitors of DYRK/CLK and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250263404-A1 | AMINOPYRIDINES AS ACTIVATORS OF PI3 KINASE | UCL BUSINESS LTD (GB) | 2025-08-21 | — | — | US | disclosed |
| US-20250051325-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2025-02-13 | — | — | US | disclosed |
| US-4983615-A | ANTIINFLAMMATORY AGENTS | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1991-01-08 | — | — | US | disclosed |
| EP-0405425-A2 | Heteroarylamino- and heteroaryloxypyridinamines and related compounds, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1991-01-02 | — | — | EP | disclosed |
| US-4970219-A | TOPICAL ANTIINFLAMMATORY AGENTS | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1990-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12528810-B2 | Small molecule inhibitors of DYRK/CLK and uses thereof | CLK3, CLK2, CLK1 | NOTUM 4876/4885HSD17B3 1419/4885CYP11B1 1588/4885 |
| US-20080221116-A1 | ISOXAZOLINE ALPHA 1a/1d ADRENORECEPTOR ANTAGONISTS | ADRA1D, ADRA1A, ADRB1 | NOTUM 4076/4885HSD17B3 126/4885CYP11B1 51/4885 |
| US-20110230478-A1 | 4-Alkyl-substituted diaminopyrimidines | DPM1, DPYD, POLR1C | NOTUM 2953/4885HSD17B3 1720/4885CYP11B1 3053/4885 |
| US-20110105472-A1 | Diaminopyrimidines as crop protection agents | DDX41, DDX1, DDX5 | NOTUM 4270/4885HSD17B3 4697/4885CYP11B1 3210/4885 |
| US-20250051325-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | CLK2, CLK1, CLK3 | NOTUM 4859/4885HSD17B3 3898/4885CYP11B1 2737/4885 |
| US-20250263404-A1 | AMINOPYRIDINES AS ACTIVATORS OF PI3 KINASE | PIK3CD, PTEN, PIK3CG | NOTUM 3648/4885HSD17B3 3768/4885CYP11B1 1374/4885 |
| US-20060116368-A1 | 4-Piperidinecarboxamide modulators of vanilloid VR1 receptor | VDAC1, TRPV1, HVCN1 | NOTUM 3548/4885HSD17B3 4207/4885CYP11B1 2534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.